Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.38 and traded as low as $2.34. Oramed Pharmaceuticals shares last traded at $2.35, with a volume of 36,845 shares trading hands.
Wall Street Analysts Forecast Growth
ORMP has been the topic of several recent research reports. StockNews.com raised shares of Oramed Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Tuesday, October 22nd. HC Wainwright reaffirmed a "neutral" rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.
Get Our Latest Stock Analysis on Oramed Pharmaceuticals
Oramed Pharmaceuticals Price Performance
The company's 50 day simple moving average is $2.38 and its two-hundred day simple moving average is $2.38. The company has a market cap of $95.40 million, a PE ratio of 4.67 and a beta of 1.77.
Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share for the quarter, beating analysts' consensus estimates of $0.01 by $0.21. Sell-side analysts expect that Oramed Pharmaceuticals Inc. will post 0.24 EPS for the current fiscal year.
Institutional Investors Weigh In On Oramed Pharmaceuticals
Several large investors have recently added to or reduced their stakes in ORMP. XTX Topco Ltd acquired a new position in shares of Oramed Pharmaceuticals in the second quarter worth $40,000. Virtu Financial LLC acquired a new position in Oramed Pharmaceuticals during the 1st quarter worth $68,000. Dimensional Fund Advisors LP increased its holdings in Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company's stock worth $81,000 after purchasing an additional 10,774 shares during the period. Renaissance Technologies LLC raised its position in Oramed Pharmaceuticals by 89.0% in the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company's stock valued at $593,000 after purchasing an additional 108,700 shares in the last quarter. Finally, Murchinson Ltd. boosted its stake in shares of Oramed Pharmaceuticals by 31.4% in the 1st quarter. Murchinson Ltd. now owns 1,379,495 shares of the biotechnology company's stock valued at $4,028,000 after buying an additional 329,495 shares during the period. 12.73% of the stock is owned by hedge funds and other institutional investors.
About Oramed Pharmaceuticals
(
Get Free Report)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
See Also
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
